Loading clinical trials...

Project Aura: Co-design of a Home-based Monitoring Service | Clinical Trials | Clareo Health

WITHDRAWN

Project Aura: Co-design of a Home-based Monitoring Service

Project Aura: Co-design of a Home-based Monitoring Service for Patients With Chronic Kidney Disease

NCT04112615•Entia Ltd

View on ClinicalTrials.gov

Summary

Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.

Detailed Description

The device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameter, participants are able to monitor their haemoglobin level at home. The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition. This study is a unique opportunity to gain feedback on the future design and development of a home-based monitoring system through user evaluation. As this is an adaptive/ iterative study design, this will give the Sponsor the opportunity to make changes to the user interface and user platform based on the feedback received from the end user.

Eligibility

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For patients:
•Adequate English to participate in focus groups without an interpreter
•Patients of the study site who are currently undergoing treatment for anaemia of CKD
•Patients willing to participate in at least one or more 60-minute and ideally 90-minute focus groups at the designated study location, time and date.
•Patients capable of providing informed consent before attending the first focus group
•For carers:
•Should be willing to participate in at least 60-minute and ideally 90-minute focus groups at the designated study location, time and date.
•Carers can only participate in the study with the patient he/she is caring for. The patient has also to be involved in the study
•Carers need to be capable of providing informed consent before attending the first focus group
•For healthcare professionals:
+12 more criteria

Exclusion Criteria

•Patients:
•Does not have adequate English to participate in focus group interviews without an interpreter.
•Patients of the study site who are not currently undergoing treatment or have previously undergone treatment within the past 12 months.
•Patients not willing to participate in at least 60-minute and ideally 90-minute focus group discussion at the designated study location, time and date.
•Participant not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the focus group interview.
•For carers:

Locations (1)

Hull University Teaching Hospitals NHS Trust

Hull, United Kingdom

Key Dates

Start Date

February 17, 2020

Primary Completion Date

June 15, 2020

Completion Date

June 15, 2020

Last Updated

February 10, 2021

Conditions

Anemia of Chronic Kidney Disease

Interventions

Blood measurement

DEVICE

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

NCT05515367

Chronic Kidney DiseasesAnemia of Chronic Kidney Disease

View study

WITHDRAWNPHASE3

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

NCT05082584

Anemia of Chronic Kidney Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Project Aura: Co-design of a Home-based Monitoring Service

Inclusion Criteria

Exclusion Criteria

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients

Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients

Desidustat in the Treatment of Chemotherapy Induced Anemia